FUJIFILM Cellular Dynamics Launches New Manufacturing Facility in Madison - Aims to Quadruple its iPSC Manufacturing Capacity

FUJIFILM Cellular Dynamics Inc., a pioneering global developer and manufacturer of human-iPSCs, celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product portfolio. With an eye toward future demand for contract manufacturing of cell therapy products, the facility is designed to be scalable to accommodate a wide range of processes, from investigational drug manufacturing to commercial production.

Maximize Exosome Yields in a Chemically Defined Media System

RoosterHD™-EV is a highly productive, chemically defined media system designed for scalable exosome production in bioreactors that maximizes yields while simplifying downstream purification. By leveraging a single media, from initial seeding through exosome harvest, realize a 10 to 20-fold increase in yields without the need for multiple media exchanges or wash steps to greatly reduce the cost to manufacture exosomes at scale.

BBG Advanced Therapies Launches Mobile Leukapheresis Center in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients 

SAN ANTONIO, TX, July 7, 2026 – BBG Advanced Therapies, a subsidiary of nonprofit BioBridge Global (BBG), announced a collaboration with Kite, a Gilead Company and global leader in cell therapy, to deploy BBG Advanced Therapies’ Mobile Leukapheresis Center (MLC) across Texas — marking an important milestone in how patients can access Kite’s CAR T-cell therapies which are individualized cancer treatments made from a patient’s own cells.

Hopstem’s iPSC-derived neural progenitor cell injection earns FDA RMAT designation for chronic stroke

HOUSTON, June 03, 2026 – Hopstem Biotechnology, a clinical-stage biotech specializing in iPSC-derived cell therapeutics for neurological diseases, has secured the first Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for its proprietary iPSC-derived human forebrain neural progenitor cell injection, hNPC01. The candidate has displayed potential for treating persistent motor dysfunction due to basal ganglia ischemic stroke in phase I clinical study.

China’s First Approved MSC Therapy, Ruibosheng, Hits the Market at a Fraction of Global Pricing

For years, the promise of MSC therapy has faced a stubborn barrier: cost. Even as regulators in South Korea, Japan, and other countries have cleared MSC-based products for commercial use, pricing for advanced cell therapies has often reached six figures.  China’s first approved MSC therapy is challenging that assumption. Ruibosheng (amimestrocel injection), developed by Platinum Life Excellence Biotech, has entered the Chinese market at a price point that is a fraction of comparable cell therapies globally, highlighting how manufacturing innovation and scale may reshape the economics of regenerative medicine.

Osaka’s Cell Grand Clinic Named Top Regenerative Medicine Solution Provider in APAC 2026 — Standardizes Patient-Specific ADSC Therapy Across 13 Government-Certified Programs

OSAKA, Japan, July 1, 2026 — Cell Grand Clinic (CGC), a Japanese government-certified regenerative medicine clinic, has been named Top Regenerative Medicine Solution Provider in APAC 2026 by Healthcare Business Review APAC, recognition that places CGC among the region’s top 10 regenerative medicine providers. The clinic operates 13 Ministry of Health, Labour and Welfare (MHLW)-certified treatment plans — among the highest concentrations in Osaka — using autologous adipose-derived stem cell (ADSC) therapy for conditions spanning knee OA, type 1 and type 2 diabetes, arteriosclerosis, age-related decline and whole-body anti-aging (frailty), and dermatologic and androgenetic applications.

Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance

CRANBURY, N.J. and SUZHOU, China, July 8, 2026 — Recently, Porton Advanced proudly announced that its Umbilical Cord-Derived Mesenchymal Stem Cell (UC-MSCs) Cell Bank for exosome manufacturing has been accepted for filing by the FDA’s Center for Biologics Evaluation and Research (CBER), under Drug Master File (DMF) #32973. This milestone further strengthens Porton Advanced’s position in the rapidly evolving exosome therapeutics market. With the DMF filing, sponsors advancing exosome programs can reference DMF #32973 in their own regulatory submissions, significantly accelerating U.S. FDA review pathways and reducing duplicative documentation.

Longevity Medical Institute® Launches Advanced Intranasal Regenerative Neurological Therapy Platform

SAN JOSÉ  DEL CABO, BAJA CALIFORNIA SUR, MEXICO, July 23, 2026 — Longevity Medical Institute^® announced the launch of its Regenerative Neurological Therapy Program, featuring an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. The technology expands the institute’s comprehensive neurological program by offering patients a non-invasive alternative to intrathecal administration for selected neurological conditions.

UniXell Biotechnology Secures FDA IND Clearance for UX-DA003, Achieving China-U.S. Dual Breakthrough in iPSC Parkinson’s Therapy

SHANGHAI, June 23, 2026 — UniXell Biotechnology has secured IND clearance from the U.S. FDA for UX-DA003, its allogeneic iPSC-derived therapy for Parkinson’s disease. Paired with the prior IND approval from China’s NMPA on June 3, 2026, the candidate will undergo clinical development in both China and the U.S. concurrently, marking a landmark dual-country breakthrough for the company’s neurodegenerative disease pipeline. This milestone solidifies UniXell’s unique dual-pathway clinical strategy covering personalized autologous and scalable off-the-shelf allogeneic iPSC therapeutics.

Anja Health Expands Partnership with Vitalant Cord Blood Stem Cell Laboratory to Advance Newborn Stem Cell Preservation

LOS ANGELES, CA, UNITED STATES, June 16, 2026 — Anja Health, a leading provider of newborn stem cell preservation services, announced the expansion of its partnership with the Vitalant Cord Blood Stem Cell Laboratory, one of the nation’s most respected stem cell processing and storage facilities, further strengthening Anja Health’s commitment to providing families with advanced cord blood, cord tissue, and placenta stem cell preservation services.

MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Knee Osteoarthritis

CAMBRIDGE, Mass., July 8, 2026 — MEDIPOST Inc., a biotech company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced the treatment of the first U.S. participant in its Phase III trial evaluating its investigational MSC therapy to treat symptomatic cartilage defects in adults with knee OA. The FDA has agreed that this single pivotal study, supported by confirmatory evidence from prior Phase 3 trials in South Korea and Japan together with Korean real-world evidence, can serve as the basis for MEDIPOST’s planned U.S. BLA filing. The milestone marks a significant step forward in MEDIPOST’s mission to bring a first-of-its-kind regenerative therapy to patients in the U.S. 

INmune Bio and Anthony Nolan Expand Collaboration to Secure Umbilical Cord Tissue Supply for CORDStrom™ Cell Therapy Platform

LONDON, UK and BOCA RATON, FL — INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based charity that set up the world’s first stem cell register and is now driving forward cell therapy advancements, signed an amended and restated Material Transfer and License Agreement. This expanded collaboration secures the long-term provision of high-quality umbilical cord tissue to power INmune Bio’s CORDStrom™ platform, the industry’s most advanced MSC technology designed to deliver consistent, scalable, and “off-the-shelf” cellular therapies which are suitable for supply in UK, EU and US, and beyond.

Cord Blood Industry Consolidation Escalates in 2026

The global cord blood industry experienced strong growth from the early 1990s through the late 2000s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space. Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half. Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America.

Exosomes as a New Class of Cell-Free Therapeutics and Diagnostics

Exosomes are a means of cell-to-cell communication and intercellular macromolecular transport. They have been found to play an important role in the transmission of proteins, lipids, mRNAs, miRNAs, and DNA, and to play a role in many diseases. This particular feature of exosomes can be exploited by using them as natural carriers of drug payloads. The contents of the exosomes can serve as useful cancer biomarkers or as biomarkers for other indications, such as neurodegenerative diseases. Such uses have compelled a rapid rise in exosome-mediated biomarker research, including the use of exosomes for the detection, monitoring, and treatment of a diverse range of oncologic conditions.

The Emerging Role of Exosome Therapeutics in 2026

Exosomes carry cell-specific cargos of proteins, lipids, and nucleic acids that are selectively taken up by recipient cells. Companies participating in exosome sector are of two types: companies using “naïve” exosomes and companies using “engineered” exosomes. Naïve exosomes are the exosomes naturally released by cells, while “engineered” exosomes are those loaded with additional biomolecules in the laboratory. Today, there are approximately 45,100+ articles published about exosomes on PubMed.gov, of which an astounding 58% were released in the past five years.

[JUST RELEASED - FLASH SALE] Global Regenerative Medicine Industry Database, 2026 - Featuring 1,940+ Companies

This global database has been updated for August 2026, with 58 newly added companies — including the latest wave of CAR-T, CAR-NK, in vivo gene editing, iPSC-derived, and organoid-based regenerative platforms — reflecting recent funding rounds, clinical milestones, market launches, and of course, our own industry relationships. Companies that have gone out of business have been removed and companies that have merged have been consolidated. Importantly, this global database was created, vetted, and verified by BioInformant’s human analysts, not AI, who have extensive experience tracking rapidly evolving RM markets. Claim this database to immediately access the identities and technical focus of every known regenerative medicine company worldwide, without the need for research, time, or effort.

This week only, you can claim it for an unusual 50% off.

Interested to learn about other market segments, such as MSCs, iPSCs, CAR-T cells, exosomes, cord blood, or the cell therapy industry at large? 

To view all available products, explore the BIOINFORMANT SHOP. 

*Interested to advertise in this newsletter? Contact Info@BioInformant.com